- Home
- ALTO vs SABS Comparison
ALTO vs SABS Comparison
Compare ALTO & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | SABS |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 198.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALTO | SABS |
|---|---|---|
| Price | $2.72 | $4.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.50 | ★ $9.80 |
| AVG Volume (30 Days) | ★ 864.9K | 465.5K |
| Earning Date | 03-04-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $922,309,000.00 | $114,698.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $1.00 |
| 52 Week High | $3.18 | $6.60 |
Technical Indicators
Market Signals| Indicator | ALTO | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 45.22 |
| Support Level | $2.51 | $4.27 |
| Resistance Level | $2.85 | $4.68 |
| Average True Range (ATR) | 0.21 | 0.26 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 28.31 | 15.12 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.